Related Experiment Video

Updated: Jul 9, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.0K

Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel

Dechao Feng1,2,3, Jie Wang1, Dengxiong Li1

  • 1Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.

Aging and Disease
|November 29, 2023
PubMed

Insights

Prolyl 4-hydroxylase subunit beta (P4HB) plays a key role in cancer development. Targeting P4HB offers potential new therapeutic strategies for cancer patients, highlighting its oncogenic role.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Prolyl 4-hydroxylase subunit beta (P4HB) facilitates disulfide bond catalysis, crucial for endoplasmic reticulum redox homeostasis.
  • Emerging evidence implicates P4HB in cancer initiation and progression.
  • Understanding P4HB's role in human cancers is critical for therapeutic development.

Purpose of the Study:

  • To comprehensively analyze the role of P4HB across various human cancers.
  • To identify potential molecular interactions and therapeutic targets for P4HB.
  • To explore P4HB as a novel therapeutic target in oncology.

Main Methods:

  • Pan-cancer analysis of P4HB expression and its correlation with clinical outcomes.
  • Narrative review of existing literature on P4HB in cancer.
  • In silico prediction of interacting molecules and potential drug candidates targeting P4HB.

Main Results:

  • P4HB exhibits significant roles in tumorigenesis and cancer development across multiple cancer types.
  • Identification of potential molecular partners and pathways associated with P4HB.
  • Prediction of top 10 drugs that may target P4HB, offering therapeutic avenues.

Conclusions:

  • P4HB is a significant oncogenic factor with a crucial role in human cancers.
  • P4HB represents a promising therapeutic target for developing novel cancer treatments.
  • Further research into P4HB-targeting drugs could lead to new clinical opportunities.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.4K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

854

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K